 SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 GLOBE NEWSWIRE -- Satsuma Pharmaceuticals, Inc. Nasdaq: STSA, a clinical-stage biopharmaceutical company developing STS101 dihydroergotamine DHE nasal powder, a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, is scheduled to present at the Cantor Virtual Global Healthcare Conference and invites investors to participate via webcast and in one-on-one meetings. Please see additional details below: 